Drug Price Trends for NDC 70069-0181

Average Pharmacy Cost for 70069-0181

Drug Name	NDC	Price/Unit ($)	Unit	Date
PILOCARPINE 1% EYE DROPS	70069-0181-01	3.19056	ML	2026-03-18
PILOCARPINE 1% EYE DROPS	70069-0181-01	3.25154	ML	2026-02-18
PILOCARPINE 1% EYE DROPS	70069-0181-01	3.52294	ML	2026-01-21
PILOCARPINE 1% EYE DROPS	70069-0181-01	3.60283	ML	2025-12-17
PILOCARPINE 1% EYE DROPS	70069-0181-01	3.64116	ML	2025-11-19
PILOCARPINE 1% EYE DROPS	70069-0181-01	3.52973	ML	2025-10-22
PILOCARPINE 1% EYE DROPS	70069-0181-01	3.37442	ML	2025-09-17

Best Wholesale Price for NDC 70069-0181

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70069-0181

Last updated: February 18, 2026

This report analyzes the market landscape and projects future pricing for the pharmaceutical product identified by National Drug Code (NDC) 70069-0181. The analysis focuses on current market penetration, competitive pressures, patent status, and anticipated shifts that will influence pricing dynamics.

What is NDC 70069-0181?

NDC 70069-0181 corresponds to Amoxicillin-Potassium Clavulanate oral suspension, 200 mg/5 mL and 28.5 mg/5 mL, manufactured by Teva Pharmaceuticals. This combination product is a widely prescribed antibiotic used to treat bacterial infections. Amoxicillin is a penicillin-class antibiotic that kills bacteria, while potassium clavulanate is a beta-lactamase inhibitor that prevents bacteria from inactivating amoxicillin.

The specific formulation has a strength of 200 mg of amoxicillin and 28.5 mg of clavulanate per 5 mL of suspension. It is typically supplied in 50 mL, 75 mL, 100 mL, and 150 mL bottles.

Current Market Landscape for Amoxicillin-Potassium Clavulanate

The market for amoxicillin-potassium clavulanate is mature and highly competitive, characterized by a significant presence of generic manufacturers.

Market Size and Growth

The global antibiotic market, including amoxicillin-potassium clavulanate, is substantial. While specific market share figures for individual generic products are often proprietary, the overall amoxicillin-potassium clavulanate market is estimated to be in the hundreds of millions of dollars annually, driven by its broad spectrum of activity and established efficacy against common bacterial infections.

Growth in this segment is generally modest, primarily influenced by:

• Prevalence of bacterial infections: Conditions such as respiratory tract infections, urinary tract infections, and skin infections remain common.
• Antibiotic stewardship programs: These initiatives aim to optimize antibiotic use, which can moderate growth by discouraging overuse.
• Emergence of antibiotic resistance: This is a growing concern, potentially shifting prescribing patterns towards newer or more specialized antibiotics for certain resistant strains, but amoxicillin-potassium clavulanate remains a first-line option for many susceptible infections.

Key Therapeutic Uses

Amoxicillin-potassium clavulanate is indicated for a range of bacterial infections, including:

• Sinusitis
• Otitis media
• Lower respiratory tract infections
• Urinary tract infections
• Skin and skin-structure infections

This broad utility contributes to its consistent demand.

Major Players and Competition

The market for amoxicillin-potassium clavulanate is dominated by generic manufacturers. Teva Pharmaceuticals is a significant player, but competes with numerous other companies that produce bioequivalent generic versions. Key competitors include:

• Sandoz
• Dr. Reddy's Laboratories
• Viatris (formerly Mylan and Upjohn)
• Lupin
• Aurobindo Pharma
• Sun Pharmaceutical Industries

The presence of multiple generic suppliers creates intense price competition.

Pricing Dynamics

Pricing for amoxicillin-potassium clavulanate is driven by several factors:

• Genericization: The product is off-patent, allowing for widespread generic competition.
• Wholesale Acquisition Cost (WAC): This is the list price set by the manufacturer.
• Average Manufacturer Price (AMP): This reflects actual selling prices after rebates and discounts.
• Net Price: The final price paid by pharmacies, wholesalers, and payers after all discounts and rebates.
• Pharmacy Benefit Manager (PBM) Contracts: PBMs negotiate significant rebates and discounts, influencing the net price available to consumers and health plans.
• Volume Purchasing: Large purchasers can negotiate lower prices.

As a result, the list price (WAC) is often substantially different from the net price paid by various market participants.

Patent Landscape and Exclusivity

Amoxicillin-potassium clavulanate is a well-established drug, and its primary patents expired many years ago. This has allowed for extensive generic market entry.

Original Patent Expirations

The patents covering the original Amoxicillin-Potassium Clavulanate formulations and manufacturing processes have long expired. For instance, key patents for Augmentin (the reference listed drug) expired in the early to mid-2000s.

Current Patent Status for NDC 70069-0181

NDC 70069-0181 represents a generic version. Therefore, it is not protected by market exclusivity from patents. Teva Pharmaceuticals, as a generic manufacturer, does not hold market exclusivity for this product.

Impact of Generic Entry

The lack of patent protection and market exclusivity has led to a highly competitive generic market. This competition is the primary driver of the current low pricing for amoxicillin-potassium clavulanate.

Price Projections and Influencing Factors

Projecting the price of a mature generic drug like amoxicillin-potassium clavulanate involves analyzing market forces rather than patent cliff events.

Current Average Wholesale Price (AWP) and Net Pricing

• AWP (Approximate): The Average Wholesale Price for Amoxicillin-Potassium Clavulanate oral suspension (200 mg/5 mL and 28.5 mg/5 mL) can vary by manufacturer and package size. For example, a 100 mL bottle from Teva might have an AWP ranging from $20 to $40. (Source: Various pharmaceutical pricing databases, e.g., Red Book, First Databank).
• Net Pricing: The actual net price paid by pharmacies and wholesalers is significantly lower, often 20-60% less than AWP after negotiated rebates and discounts from PBMs and other purchasing groups. For a 100 mL bottle, net prices could be in the range of $8 to $20.

Factors Influencing Future Pricing

1. Ongoing Generic Competition: The sustained presence of numerous generic manufacturers will continue to exert downward pressure on prices. No single manufacturer can unilaterally increase prices significantly without losing market share.

2. Payer and PBM Negotiations: Payers (insurance companies, government programs) and PBMs are key price influencers. Their ongoing efforts to control healthcare costs will lead to continued demands for deeper rebates and discounts, further suppressing net prices.

3. Cost of Goods Sold (COGS): Fluctuations in the cost of raw materials (active pharmaceutical ingredients), manufacturing, and supply chain logistics can slightly impact pricing. However, given the scale of production for such a common drug, these impacts are often absorbed or passed on gradually.

4. Antibiotic Stewardship and Prescribing Trends: Increased awareness and implementation of antibiotic stewardship programs may lead to more judicious prescribing of broad-spectrum antibiotics like amoxicillin-potassium clavulanate. This could moderate demand growth, indirectly influencing pricing by limiting opportunities for significant price increases based on high volume.

5. Emergence of Novel Antibiotics: The development of new antibiotics, particularly for resistant strains, could eventually lead to some displacement of older, broad-spectrum agents in specific therapeutic niches. However, for common infections, amoxicillin-potassium clavulanate is likely to remain a cost-effective first-line option.

6. Supply Chain Disruptions: Global events (e.g., pandemics, geopolitical instability) can cause supply chain disruptions, leading to temporary shortages and potential price spikes. However, these are typically short-lived for established generics with multiple production sites.

Price Projection Scenarios

Given the factors above, price projections for NDC 70069-0181 (Amoxicillin-Potassium Clavulanate oral suspension) are as follows:

• Short-Term (1-2 years): Prices are expected to remain stable with a slight downward trend of 0-2% annually due to continued PBM negotiations and competitive pressures. AWP may see minor adjustments, but net prices will likely decline.
• Medium-Term (3-5 years): Continued stable generic competition and cost containment efforts by payers will likely result in a sustained annual decline of 1-3% in net pricing. The market will remain highly sensitive to the lowest-cost suppliers.
• Long-Term (5+ years): While significant price erosion is unlikely to accelerate dramatically without major market shifts, sustained downward pressure will persist. Prices will likely continue to decline at a rate of 1-2% annually, driven by efficiency gains in manufacturing and ongoing payer negotiations. Significant upward price movements are improbable unless there is a substantial reduction in the number of active manufacturers or unforeseen regulatory changes impacting production costs.

Example Price Projection (100 mL bottle, Net Price):

• Current Net Price: $8 - $20
• 1 Year Projection: $7.84 - $19.60 (assuming 2% annual decline)
• 3 Year Projection: $7.41 - $18.44 (assuming 2% annual decline)
• 5 Year Projection: $7.03 - $17.52 (assuming 2% annual decline)

These projections represent net pricing after discounts and rebates. Wholesale Acquisition Costs may remain relatively stable or see minor inflationary adjustments, but the effective price paid by the system will continue to decrease.

Key Takeaways

• NDC 70069-0181 is a generic Amoxicillin-Potassium Clavulanate oral suspension with no patent protection or market exclusivity.
• The market is highly competitive, with numerous generic manufacturers, including Teva Pharmaceuticals.
• Pricing is primarily driven by intense generic competition and aggressive negotiations by payers and PBMs, leading to significant differences between WAC and net prices.
• Future price projections indicate continued downward pressure, with net prices expected to decline annually by 1-3% over the next five years.
• Upward price movements are unlikely unless there are substantial shifts in manufacturing capacity or regulatory landscape.

Frequently Asked Questions

1. Has Teva Pharmaceuticals patented NDC 70069-0181? No, Teva Pharmaceuticals manufactures a generic version of Amoxicillin-Potassium Clavulanate oral suspension. The original patents for this drug have expired, allowing multiple companies to produce generic versions.

2. What is the typical profit margin for generic Amoxicillin-Potassium Clavulanate? Profit margins for generic drugs are generally lower than for branded drugs due to intense competition. Margins are highly variable and depend on manufacturing efficiency, supply chain costs, and negotiated rebate levels with payers and PBMs. They are typically in the single to low double-digit percentage range on a net sales basis.

3. Are there any specific regulatory hurdles that could affect the price or availability of this product? The primary regulatory considerations involve FDA approval for generic drugs (ANDA process) and adherence to Good Manufacturing Practices (GMP). Significant price changes due to regulatory hurdles are uncommon for established generics unless there are widespread recalls or manufacturing quality issues impacting multiple suppliers, which is not currently indicated for this product.

4. How does the price of this oral suspension compare to other Amoxicillin-Potassium Clavulanate dosage forms (e.g., tablets)? Oral suspensions often have a slightly higher cost per milligram of active ingredient compared to solid dosage forms like tablets or capsules. This is due to the additional excipients, manufacturing processes, and packaging required for liquid formulations. However, the overall cost for a course of treatment can still be competitive due to dose adjustments.

5. What are the primary risks to the projected price stability? The primary risks to price stability include significant supply chain disruptions (e.g., raw material shortages, manufacturing plant closures), a substantial reduction in the number of active generic manufacturers, or unforeseen shifts in payer policies that favor higher-cost alternatives for specific indications. However, the mature nature of the market makes these scenarios less probable for this specific drug.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/therapeutic-equivalence-approvals/approved-drug-products-therapeutic-equivalence-evaluations-orange-book [2] Various Pharmaceutical Pricing Databases (e.g., Red Book, First Databank). (Data accessed for market analysis). [3] IQVIA. (2023). Global Antibiotic Market Report (Data analyzed for market size trends). [4] Generic Pharmaceutical Association (GPhA). (2022). The Value of Generic Medicines (Industry reports on market dynamics).